Erythromycin

證據等級: L5

預測適應症: 5 個

Erythromycin: From Bacterial Infections to Punctate Epithelial Keratoconjunctivitis

One-Sentence Summary

Erythromycin is a classic macrolide antibiotic with proven efficacy against gram-positive bacteria and atypical intracellular pathogens (including Chlamydia trachomatis), widely used globally for respiratory, skin, and sexually transmitted infections — though it is currently not registered in the Philippines. The TxGNN model predicts potential efficacy across 5 new indications, with the top-ranked prediction being Punctate Epithelial Keratoconjunctivitis (score: 99.89%). Evidence strength varies considerably: two indications — Lymphogranuloma Venereum (1 clinical trial, 20 publications) and Necrotizing Ulcerative Gingivitis (5 publications with direct clinical records of erythromycin use) — reach L3 evidence with a Proceed with Guardrails recommendation, while the remaining three indications stand at L4–L5.

Quick Overview

Item	Content
Original Indication	Bacterial infections (macrolide antibiotic; not registered in the Philippines)
Predicted New Indication (Top Rank)	Punctate Epithelial Keratoconjunctivitis
TxGNN Prediction Score	99.89%
Evidence Level	L4
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Research Question

All Predicted Indications

Rank	Disease	TxGNN Score	Trials	Publications	Evidence Level	Decision
1	Punctate Epithelial Keratoconjunctivitis	99.89%	0	2	L4	Research Question
2	Acute Contagious Conjunctivitis	99.55%	0	0	L5	Hold
3	Exposure Keratitis	99.50%	0	8	L4	Research Question
4	Lymphogranuloma Venereum	99.05%	1	20	L3	Proceed with Guardrails
5	Necrotizing Ulcerative Gingivitis	99.00%	0	5	L3	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the DrugBank dataset. Based on well-established pharmacological information, Erythromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit and blocking peptide chain translocation. It exhibits activity against gram-positive cocci (Staphylococcus aureus, S. epidermidis, Streptococcus pneumoniae), some gram-negative organisms (Haemophilus influenzae), and critically — atypical intracellular pathogens including Chlamydia trachomatis and Mycoplasma pneumoniae.

For the top-ranked prediction (Punctate Epithelial Keratoconjunctivitis), the mechanistic rationale is plausible: common causative pathogens of this condition — S. aureus, S. epidermidis, and C. trachomatis — all fall within erythromycin’s antibacterial spectrum. Furthermore, erythromycin 0.5% ophthalmic ointment is an approved dosage form in multiple countries (including for neonatal ophthalmia prophylaxis), confirming that ocular delivery is pharmacologically feasible. However, no clinical trials or literature specifically investigate erythromycin for punctate epithelial keratoconjunctivitis, placing evidence at L4 (mechanistic support only).

The most evidence-supported prediction is Lymphogranuloma Venereum (rank 4). LGV is caused by C. trachomatis serovars L1–L3 — an organism directly susceptible to erythromycin. Historical CDC and WHO guidelines have listed erythromycin (21-day oral course) as an alternative LGV treatment regimen, with doxycycline as the current first-line and azithromycin as an accepted alternative. A 1955 clinical case series directly documents erythromycin use in early LGV (PMID: 13239093), while a 1999 UK national guideline (PMID: 10616382) explicitly includes erythromycin as an alternative antibiotic. For Necrotizing Ulcerative Gingivitis (rank 5), the causative fusospirochetal complex (Fusobacterium nucleatum, Treponema vincentii) is susceptible to macrolides; a 1953 clinical report (PMID: 13221896) directly documents erythromycin use for fusospirochetal oropharyngeal infections, and the drug remains a recognized penicillin-alternative in dental antibiotic guidelines.

Clinical Trial Evidence

One registered clinical trial was identified, relevant to Lymphogranuloma Venereum (rank 4). No trials were registered for the remaining four indications.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03608774	Phase 4	Completed	177	Randomized double-blind trial comparing azithromycin vs. doxycycline for rectal Chlamydia trachomatis in men who have sex with men (United States). The test drug is azithromycin — a related macrolide — rather than erythromycin. Both drugs share the same 50S ribosomal target and class-level antichlamydial activity, providing indirect support for erythromycin in LGV. Direct erythromycin efficacy data was not assessed in this trial.

Literature Evidence

Punctate Epithelial Keratoconjunctivitis (Rank 1)

PMID	Year	Type	Journal	Key Findings
11495307	2001	Clinical Review	J Pediatr Ophthalmol Strabismus	Diagnosis and management of chronic blepharokeratoconjunctivitis in children; discusses treatment approaches for overlapping keratoconjunctival inflammatory conditions — indirect contextual support
32826651	2021	Case Report	Cornea	Microsporidia (Encephalitozoon hellem) keratoconjunctivitis diagnosed by metagenomic deep sequencing in an immunocompetent adult; highlights pathogen diversity and diagnostic complexity in keratoconjunctivitis

Exposure Keratitis (Rank 3)

PMID	Year	Type	Journal	Key Findings
22880135	2012	Retrospective Cohort	PLoS One	Prevalence and antibiotic susceptibility of MRSA vs. MSSA in ocular infections; documents erythromycin susceptibility patterns relevant to secondary bacterial infection management in exposure keratitis
24244625	2013	Retrospective Review	PLoS One	S. aureus keratitis clinical features, antibiotic susceptibility, and outcomes; characterizes the primary pathogen of secondary infection in exposure keratitis
21902780	2012	Review	Clin Exp Ophthalmol	Non-tuberculous mycobacteria ocular infections: epidemiology, risk factors, and in vitro susceptibilities; macrolide antibiotics discussed as a treatment class
3157322	1985	Case Report	Am J Ophthalmol	Child with conjunctivitis-related erythema multiforme treated with erythromycin 0.5% ophthalmic ointment and systemic corticosteroids; documents real-world ocular application of erythromycin ointment

Lymphogranuloma Venereum (Rank 4)

PMID	Year	Type	Journal	Key Findings
13239093	1955	Clinical Case Series	Antibiotic Med Clin Ther	Direct evidence: Erythromycin–sulfonamide combination for early LGV treatment — earliest documented clinical use of erythromycin specifically for LGV
10616382	1999	Clinical Guideline	Sex Transm Infect	UK national guideline for LGV management; erythromycin explicitly listed as an alternative antibiotic regimen
3545650	1987	Review	Clin Pharm	Recognition and treatment of chlamydial infections; erythromycin cited as a first-line treatment option for genital C. trachomatis infections
2246945	1990	Review	Med Clin North Am	Comprehensive C. trachomatis infection review; erythromycin discussed as a treatment for LGV and other chlamydial syndromes including neonatal infection
22760150	2012	Case Report	Rev Soc Bras Med Trop	LGV case in a 17-year-old directly treated with erythromycin; subsequent diagnosis of non-Hodgkin lymphoma highlighted a diagnostic pitfall in the inguinal region
33462582	2021	Retrospective Case Series	Clin Infect Dis	Weekly azithromycin 1 g × 3 weeks demonstrated efficacy for LGV proctitis in MSM in Europe; provides macrolide class-level support for erythromycin
40815293	2025	Observational Study	Sex Transm Dis	LGV prevalence and treatment outcomes in gay/bisexual MSM attending STI clinics in Alberta, Canada (2018–2022); real-world macrolide treatment data
25870512	2015	Review	Infect Drug Resist	LGV diagnostic and treatment challenges; reviews antibiotic regimens and emerging difficulties with standard doxycycline therapy
30518587	2018	Systematic Review	BMJ Open	Systematic review of non-standard treatments for uncomplicated C. trachomatis infections; evaluates alternatives to first-line therapy including macrolides
22335265	2012	Review	Am Fam Physician	Diagnosis and management of genital ulcers including LGV; treatment algorithm with antibiotic options

Necrotizing Ulcerative Gingivitis (Rank 5)

PMID	Year	Type	Journal	Key Findings
13221896	1953	Clinical Case Series	J-Lancet	Direct evidence: Erythromycin (Ilotycin) for fusospirochetal infections of the oropharynx — earliest clinical documentation of erythromycin efficacy for the NUG causative organism complex
4981637	1969	Clinical Report	Chir Dent Fr	Erythromycin ethyl succinate chewable tablets in dentistry; documents clinical value for oral and dental infections
6589179	1984	Review	Dent Clin North Am	Antibiotics in dental practice; erythromycin listed as first-choice alternative for penicillin-allergic patients treating typical dental infections
36268928	2022	Narrative Review	Eur J Transl Myol	Antibiotic use in endodontic treatment during pregnancy; erythromycin identified as a safe alternative for penicillin-allergic pregnant patients with odontogenic infections
1254998	1976	Review	J Laryngol Otol	Overview of oral vesiculobullous and ulcerative lesions; contextualizes oral bacterial infection management including antibiotic options for acute necrotizing gingivitis

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails (Lymphogranuloma Venereum and Necrotizing Ulcerative Gingivitis) Research Question (Punctate Epithelial Keratoconjunctivitis and Exposure Keratitis) Hold (Acute Contagious Conjunctivitis)

Rationale: Erythromycin has well-established activity against the causative pathogens of LGV (C. trachomatis) and NUG (fusospirochetal complex), supported by direct clinical case series dating to 1953–1955, inclusion in historical treatment guidelines, and indirect evidence from macrolide-class trials — sufficient to proceed with a structured research protocol. The three ocular indications are mechanistically plausible given erythromycin’s approved ophthalmic formulation globally, but they lack direct clinical trial evidence and require formal investigation before proceeding. Acute contagious conjunctivitis has zero supporting literature and should be deferred. The critical cross-cutting barrier is that erythromycin has no current Philippines market registration, which must be resolved before any clinical deployment.

To proceed, the following is needed:

Philippines regulatory pathway: Investigate Philippine FDA registration requirements for erythromycin — particularly oral formulations (for LGV/NUG) and 0.5% ophthalmic ointment (for ocular indications)
Safety profile retrieval: Obtain package insert to assess key warnings, contraindications, and drug interactions — currently unavailable and flagged as a blocking data gap
MOA documentation: Retrieve complete DrugBank pharmacology and mechanism of action data to strengthen mechanistic rationale across all five indications
LGV clinical study (Rank 4, L3 → target L2): Design a randomized trial comparing erythromycin to doxycycline for LGV in the Philippine context, with particular focus on populations where doxycycline is contraindicated (e.g., pregnancy)
NUG clinical study (Rank 5, L3 → target L2): Conduct a prospective cohort study evaluating erythromycin vs. metronidazole ± amoxicillin for NUG in penicillin-allergic patients in Philippine dental clinics
Ophthalmic indications (Ranks 1 & 3, L4 → target L3): Confirm ophthalmic formulation availability and supply chain in the Philippines; design a pilot clinical trial for punctate epithelial keratoconjunctivitis with microbiological confirmation of susceptible pathogens
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.